title: Acute liver failure related to chemotherapy.
abstract: Hepatitis B virus (HBV) reactivation is a serious but preventable complication of immunosuppression. Chemotherapy in patients with lymphoma without specific anti-HBV prophylaxis leads to significant impairment of liver function and results in an overall liver-related mortality of greater than 5%. Prevention is a better approach than intervention at the time of reactivation. The cause of death is usually HBV-related fulminant liver failure. We reported a case of a male patient aged 42 years old who was present with acute liver failure related to chemotherapy for treatment of gastric lymphoma. He was later known as having chronic carrier hepatitis B, with high elevated transaminases and hyperbilirubinemia and signs of decompensated liver. The patient was admitted to High Care Unit for best supportive care but his condition was deteriorating and eventually died eventhough he had been already given antiviral agent.
authors: Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo Hospital. Jl. Diponegoro no. 71, Jakarta Pusat 10430, Indonesia. leon_natan@yahoo.com
authors: Indra
authors: I
authors: Wijaya
authors: Andri
authors: A
authors: Sanityoso
authors: Laurentius A
authors: LA
authors: Lesmana
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D017809:Fatal Outcome; D006515:Hepatitis B virus / Q000187:drug effects* / Q000254:growth & development; D019694:Hepatitis B, Chronic / Q000821:virology*; D006801:Humans; D017114:Liver Failure, Acute / Q000821:virology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D000069283:Rituximab; D013274:Stomach Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone